Ocular Therapeutix (OCUL) Accumulated Depreciation (2013 - 2025)

Ocular Therapeutix's Accumulated Depreciation history runs 13 years deep, the most recent figure standing at $27.5 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 16.45% year-over-year to $27.5 million; the TTM figure through Dec 2025 stood at $27.5 million (up 16.45% YoY), while the FY2025 annual figure was $27.5 million, up 16.45% from the prior year.
• Accumulated Depreciation was $27.5 million for Q4 2025 at Ocular Therapeutix, up from $23.6 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $27.5 million in Q4 2025 to a low of $15.2 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $20.8 million across 5 years, with a median of $20.3 million in 2023.
• The sharpest annual moves came in 2021 and 2022: Accumulated Depreciation grew 18.93% in 2021, then climbed 13.62% in 2022.
• A 5-year view of Accumulated Depreciation shows it stood at $15.2 million in 2021, then climbed by 13.62% to $17.3 million in 2022, then rose by 17.26% to $20.3 million in 2023, then rose by 16.64% to $23.6 million in 2024, then rose by 16.45% to $27.5 million in 2025.
• The last three Accumulated Depreciation figures came in at $27.5 million (Q4 2025), $23.6 million (Q4 2024), and $20.3 million (Q4 2023), per Business Quant data.